Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 19 results.
User Information
Export Records
  1. 1.   Targeting the extrinsic apoptosis signaling pathway for cancer therapy
  2. Sayers, T. J.
  3. Cancer Immunology Immunotherapy. 2011, Aug; 60(8): 1173-1180.
  1. 2.   Carminomycin I Is an Apoptosis Inducer That Targets the Golgi Complex in Clear Cell Renal Carcinoma Cells
  2. Woldemichael, G. M.; Turbyville, T. J.; Linehan, W. M.; McMahon, J. B.
  3. Cancer Research. 2011, Jan; 71(1): 134-142.
  1. 3.   Ras(V12)-Mediated Down-regulation of CCAAT/Enhancer Binding Protein beta in Immortalized Fibroblasts Requires Loss of p19(Arf) and Facilitates Bypass of Oncogene-Induced Senescence
  2. Sebastian, T.; Johnson, P. F.
  3. Cancer Research. 2009 69(6): 2588-2598.
  1. 4.   Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
  2. Shanker, A.; Brooks, A. D.; Tristan, C. A.; Wine, J. W.; Elliott, P. J.; Yagita, H.; Takeda, K.; Smyth, M. J.; Murphy, W. J.; Sayers, T. J.
  3. Journal of the National Cancer Institute. 2008 100(9): 649-662.
  1. 5.   The role of protein binding in induction of apoptosis by phenethyl isothiocyanate and sulforaphane in human non-small lung cancer cells
  2. Mi, L. X.; Wang, X. T.; Govind, S.; Hood, B. L.; Veenstra, T. D.; Conrads, T. P.; Saha, D. T.; Goldman, R.; Chung, F. L.
  3. Cancer Research. 2007, Jul; 67(13): 6409-6416.
  1. 6.   CDK2 is required by MYC to induce apoptosis
  2. Deb-Basu, D.; Aleem, E.; Kaldis, P.; Felsher, D. W.
  3. Cell Cycle. 2006, Jun; 5(12): 1342-1347.
  1. 7.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 8.   Inhibition of transcription factor NF-kappa B signaling proteins IKK beta and p65 through specific cysteine residues by epoxyquinone A monomer: Correlation with its anti-cancer cell growth activity
  2. Liang, M. C.; Bardhan, S.; Pace, E. A.; Rosman, D.; Beutler, J. A.; Porco, J. A.; Gilmore, T. D.
  3. Biochemical Pharmacology. 2006, FEB 28; 71(5): 634-645.
  1. 9.   Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma
  2. Khan, T.; Hixon, J. A.; Stauffer, J. K.; Lincoln, E.; Back, T. C.; Brenner, J.; Lockett, S.; Nagashima, K.; Powell, D.; Wigginton, J. M.
  3. Journal of the National Cancer Institute. 2006, FEB 1; 98(3): 190-202.
  1. 10.   TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer
  2. Cretney, E.; Shanker, A.; Yagita, H.; Smyth, M. J.; Sayers, T. J.
  3. Immunology and Cell Biology. 2006, FEB; 84(1): 87-98.
  1. 11.   Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
  2. Sayers, T. J.; Murphy, W. J.
  3. Cancer Immunology Immunotherapy. 2006, JAN; 55(1): 76-84.
  1. 12.   Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity
  2. Sun, K.; Wilkins, D. E. C.; Anver, M. R.; Sayers, T. J.; Panoskaltsis-Mortari, A.; Blazar, B. R.; Weiniak, L. A.; Murphy, W. J.
  3. Blood. 2005, NOV 1; 106(9): 3293-3299.
  1. 13.   Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis
  2. Brooks, A. D.; Sayers, T. J.
  3. Cancer Immunology Immunotherapy. 2005, MAY; 54(5): 499-505.
  1. 14.   Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation
  2. Puppo, M.; Pastorino, S.; Melillo, G.; Pezzolo, A.; Varesio, L.; Bosco, M. C.
  3. Clinical Cancer Research. 2004, DEC 15; 10(24): 8704-8719.
  1. 15.   Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XLAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database
  2. Nikolovska-Coleska, Z.; Xu, L.; Hu, Z. J.; Tomita, Y.; Li, P.; Roller, P. P.; Wang, R. X.; Fang, X. L.; Guo, R. B.; Zhang, M. C.; Lippman, M. E.; Yang, D. J.; Wang, S. M.
  3. Journal of Medicinal Chemistry. 2004 47(10): 2430-2440.
  1. 16.   NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade
  2. Koh, C. Y.; Ortaldo, J. R.; Blazar, B. R.; Bennett, M.; Murphy, W. J.
  3. Blood. 2003 102(12): 4067-4075.
  1. 17.   PUMA, a novel proapoptotic gene, is induced by p53
  2. Nakano, K.; Vousden, K. H.
  3. Molecular Cell. 2001 7(3): 683-694.
  1. 18.   p53: Death star
  2. Vousden, K. H.
  3. Cell. 2000 103(5): 691-694.
  1. 19.   E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways
  2. Phillips, A. C.; Ernst, M. K.; Bates, S.; Rice, N. R.; Vousden, K. H.
  3. Molecular Cell. 1999 4(5): 771-781.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel